NASDAQ · NMRA
Healthcare · Biotechnology
$1.04
Down-$0.10 (-8.77%)
Updated Sep 12, 2026, 5:53 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NMRA closed at $1.04 after 20 trading sessions, down 35.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.16 | $1.16 | $1.02 | $1.04 | 1.88M |
| Sep 10, 2026 | $1.20 | $1.21 | $1.115 | $1.14 | 600.85K |
| Sep 9, 2026 | $1.26 | $1.265 | $1.19 | $1.20 | 586.95K |
| Sep 8, 2026 | $1.29 | $1.34 | $1.24 | $1.25 | 757.24K |
| Sep 4, 2026 | $1.35 | $1.36 | $1.29 | $1.31 | 549.21K |
| Sep 3, 2026 | $1.39 | $1.39 | $1.34 | $1.35 | 386.04K |
| Sep 2, 2026 | $1.35 | $1.41 | $1.345 | $1.38 | 532.23K |
| Sep 1, 2026 | $1.33 | $1.36 | $1.31 | $1.33 | 532.62K |
| Aug 31, 2026 | $1.40 | $1.445 | $1.32 | $1.33 | 633.1K |
| Aug 28, 2026 | $1.50 | $1.51 | $1.38 | $1.39 | 696.29K |
| Aug 27, 2026 | $1.55 | $1.575 | $1.48 | $1.48 | 534.04K |
| Aug 26, 2026 | $1.50 | $1.57 | $1.46 | $1.56 | 536.19K |
| Aug 25, 2026 | $1.53 | $1.57 | $1.48 | $1.50 | 475.57K |
| Aug 24, 2026 | $1.58 | $1.65 | $1.51 | $1.525 | 1.16M |
| Aug 21, 2026 | $1.51 | $1.64 | $1.51 | $1.63 | 499.11K |
| Aug 20, 2026 | $1.61 | $1.63 | $1.475 | $1.515 | 1.49M |
| Aug 19, 2026 | $1.65 | $1.71 | $1.615 | $1.64 | 716.17K |
| Aug 18, 2026 | $1.50 | $1.65 | $1.48 | $1.64 | 781.77K |
| Aug 17, 2026 | $1.55 | $1.585 | $1.46 | $1.52 | 1.35M |
| Aug 14, 2026 | $1.69 | $1.71 | $1.58 | $1.60 | 1.17M |
The latest Smart Investors Daily articles mentioning NMRA.
NMRA research
Company profile and research snapshot.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | RBC Capital | Outperform | — |
| Jun 18, 2026 | Mizuho | Outperform | — |
| Jun 16, 2026 | Needham | Buy | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share
Benzinga · Jul 31, 2026
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
Benzinga · Jul 27, 2026
Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent
Benzinga · Jul 13, 2026
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NMRA.
